Crystal Structure of the Catalytic Domain of Human Matrix Metalloproteinase 10

Journal of Molecular Biology

Volumn 336, Issue 3, 2004, Pages 707-716

  Bertini, I ^a,b   Calderone, V ^a,c   Fragai, M ^a,b   Luchinat, C ^a,b   Mangani, S ^a,c   Terni, B ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ProtEra Srl   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Crystal structure; Inhibitor; Matrix metalloproteinase; MMP 10; Stromelysin 2

Indexed keywords

STROMELYSIN 2;

ARTICLE; BIOAVAILABILITY; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA SEQUENCE; ENZYME DEGRADATION; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE;

ESCHERICHIA COLI;

EID: 0842289659     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.12.033     Document Type: Article

References (45)

1. Birkedal-Hansen H. Proteolytic remodelling of extracellular matrix. Curr. Opin. Cell Biol. 7:1995;728-735.
2. Murphy G.J., Murphy G., Reynolds J.J. The origin of matrix metalloproteinases and their relationship. FEBS Letters. 89:1991;4-7.
3. Overall C.M., Lopéz-Otín C. Strategies for MMP inhibition in cancer: innovation for the post-trial era. Nature Rev. Cancer. 2:2002;657-672.
4. Andreini, C., Banci, L., Bertini, I., Luchinat, C., & Rosato, A. (2003). A bioinformatic comparison of structures and homology-models of matrix metalloproteinases. J. Proteome Res. In the press.
5. Borkakoti N. Matrix metalloproteases: variations on a theme. Prog. Biophys. Mol. Biol. 70:1998;73-94.
6. Marchenko G.N., Ratnikov B.I., Rozanov D.V., Godzik A., Deryugina E.I., Strongin A.Y. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem. J. 356:2001;705-718.
7. Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., Tryggvason K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science. 284:1999;1667-1670.
8. Elkins P.A., Ho Y.S., Smith W.W., Janson C.A., D'Alessio K.J., McQueney M.S., et al. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallog. sect. D. 58:2002;1182-1192.
9. Stetler-Stevenson W.G., Hewitt R. Matrix metalloproteinases and tumor invasion: from correlation and causuality to the clinic. Semin. Cancer Biol. 7:1996;147-154.
10. Borkakoti N. Structural Studies of matrix metalloproteases. J. Mol. Med. 78:2000;261-268.
11. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996;299-302.
12. Whittaker M., Floyd C.D., Brown P., Gearing A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99:1999;2735-2776.
13. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2002;2387-2392.
14. Hoekstra R., Eskens F.A., Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist. 6:2001;415-427.
15. Briknarova K., Gehrmann M., Banyai L., Tordai H., Patthy L., Llinas M. Gelatin-binding region of human matrix metalloproteinase-2: solution structure, dynamics, and function of the COL-23 two-domain construct. J. Biol. Chem. 276:2001;27613-27621.
16. Trexler M., Briknarova K., Gehrmann M., Llinas M., Patthy L. Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). J. Biol. Chem. 278:2003;12241-12246.
17. Spurlino J.C., Smallwood A.M., Carlton D.D., Banks T.M., Vavra K.J., Johnson J.S., et al. Structure of mature truncated human fibroblast collagenase. Proteins: Struct. Funct. Genet. 19:1994;98-109.
18. Pavlovski A.G., Williams M.G., Ye Q.-Z., Ortwine D.F., Purchase C.F. II, White A.D., et al. X-ray structure of human stromelysin catalytic domain complexed with non-peptide inhibitors: implications for inhibitor selectivity. Protein Sci. 8:1999;1455-1462.
19. Browner M.F., Smith W.W., Castelhano A.L. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry. 34:1995;6602-6610.
20. Gavuzzo E., Pochetti G., Mazza F., Gallina C., Gorini B., D'Alessio S., et al. Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design. J. Med. Chem. 43:2000;3377-3385.
21. Rowsell S., Hawtin P., Minshull C.A., Jepson H., Brockbank S.M., Barratt D.G., et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 319:2002;173-181.
22. Lang R., Kocourek A., Braun M., Tschesche H., Huber R., Bode W., Maskos K. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 Å crystal structure. J. Mol. Biol. 312:2001;731-742.
23. Nar H., Werle K., Bauer M.M.T., Dollinger H., Jung B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J. Mol. Biol. 312:2001;743.
24. Bertini I., Calderone V., Fragai M., Luchinat C., Mangani S., Terni B. X-ray structures of ternary enzyme-product-inhibitor complexes of MMP. Angew. Chem. Int. Ed. 42:2003;2673-2676.
25. Moy F.J., Chanda P.K., Chen J.M., Cosmi S., Edris W., Levin J.I., Powers R. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. J. Mol. Biol. 302:2000;671-689.
26. Fernandez-Catalan C., Bode W., Huber R., Turk D., Calvete J.J., Lichte A., et al. Crystal structure of the complex formed by membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J. 17:1998;5238-5248.
27. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17:2001;463-516.
28. Bord S., Horner A., Hembry R.M., Compston J.E. Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone: potential roles in skeletal development. Bone. 23:1998;7-12.
29. Jeng A.Y., Chou M., Parker D.T. Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase. Bioorg. Med. Chem. Letters. 8:1998;897-902.
30. MacPherson L.J., Bayburt E.K., Capparelli M.P., Carroll B.J., Goldstein R., Justice M.R., et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 40:1997;2525-2532.
31. Natchus M.G., Bookland R.G., Laufersweiler M.J., Pikul S., Almstead N.G., De B., et al. Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines. J. Med. Chem. 44:2001;1060-1071.
32. Pikul S., Dunham K.M., Almstead N.G., De B., Natchus M.G., Taiwo Y.O., et al. Heterocycle-based MMP inhibitors with P2′ substituents. Bioorg. Med. Chem. Letters. 11:2001;1009-1013.
33. Banci L., Bertini I., Ciulli A., Fragai M., Luchinat C., Terni B. Expression and high yield production of matrix metalloproteinase 12 and of an active mutant with increased solubility. J. Mol. Catal. 204-205:2003;401-408.
34. Leslie A.G.W. In crystallographic computing V. Moras D., Podjarny A.D., Thierry J.-C. Molecular Data Processing. 1991;50-61 Oxford University Press, Oxford.
35. Evans, P. R. (1993) Data Reduction. Proceedings of CCP4 Study Weekend. Data Collection & Processing, 114-122. (GENERIC).
36. Rossmann M.G., Blow D.M. The detection of sub-units within the crystallographic asymmetric unit. Acta Crystallog. 15:1962;24-31.
37. Crowther R.A. Rossmann M.G. The Molecular Replacement Method. 1972;Gordon & Breach, New York.
38. Vagin A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallog. 30:1997;1022-1025.
39. Vagin A., Teplyakov A. An approach to multi-copy search in molecular replacement. Acta Crystallog. sect. D. 56 Pt 12:2000;1622-1624.
40. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D. 54:1998;905-921.
41. Collaborative Computational Project, Number 4 (1994). The CCP4 Suite: programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-763.
42. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D. 53:1997;240-255.
43. McRee D.E. XtalView: a visual protein crystallographic software system for XII/XView. J. Mol. Graph. 10:1992;44-47.
44. Lamzin V.S., Wilson K.S. Automated refinement of protein models. Acta Crystallog. sect. D. 49:1993;129-149.
45. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26:1993;283-291.